In an era where genetic disorders and cancer cases continue to rise globally, the role of molecular cytogenetics is becoming increasingly critical. This field has the potential to revolutionize health outcomes through precise characterization of chromosome abnormalities, helping draw the line between a misdiagnosis and an accurate understanding of the condition at hand.
The molecular cytogenetics market is experiencing a significant upturn, fueled by ongoing research studies, advancements in technology, and an increasing prevalence of diseases like cancer. Molecular cytogenetics plays a vital role in understanding various genetic disorders such as Down syndrome, Edwards' syndrome, Patau syndrome, and Turner syndrome, making it an indispensable tool in the current disease landscape.
Not only does molecular cytogenetics provide crucial information for treatment strategies, it is fundamental in researching the genes causing these conditions, thus giving impetus to the development of personalized medicine. Technological advancements are making cytogenetic research data analysis more convenient and efficient, opening new opportunities for market growth. Despite challenges such as high treatment costs and lack of awareness about emerging diagnostic technologies, the molecular cytogenetics market is projected to witness significant growth in the forecast period.
COVID-19 had a significant impact on the molecular cytogenetics market. During the pandemic, the alternation in genetic materials in affected persons was identified through the help of cytogenetics. For instance, as per the article published in July 2021 in Nature journal, genetic factors influencing COVID-19 susceptibility and severity offered new biological insights into disease etiology and identify molecular targets for therapeutic development or medication repurposing. In the current situation, as the restrictions are lifted the market is expected to witness growth in the coming years due to the rise in utilization of cytogenetic research studies and the increase in the genetic disease population.
The growing prevalence of cancer and genetic disorders directly impacts the increased demand for the molecular cytogenetic market. For instance, as per the American Cancer Society, 1.9 million people are estimated to be diagnosed with cancer in the United States in 2022. Cancer cytogenetics not only gives important information to help with the treatment of cancer patients but also serves as a guide to finding the genes that cause these neoplastic states, which has stimulated the development of molecularly targeted therapies in the area of personalized medicine. Thus, the rise in cancer cases is anticipated to increase market growth over the forecast period.
Furthermore, the genetic data accumulated each day are closely associated with the diagnosis and prognosis of neoplasm, thus widening the scope of cancer cytogenetics in various practices. Molecular cytogenetics has numerous applications in a number of genetic diseases such as Down syndrome, Edwards' syndrome, Patau syndrome, and Turner syndrome. For instance, as per the article published in March 2022 in Molecular Cytogenetics journal, the researchers reported a rare mosaic X-ring chromosome in a patient with Turner syndrome that had highly variable phenotypes through the cytogenetic microarray experiment. The researchers identified the phenotype in terms of clinical symptoms, ultrasound diagnosis, and cytogenetics, of the patient with a rare genotype and Turner syndrome. Thus, such studies utilizing the application of cytogenetics are expected to drive market growth over the forecast period. Similarly, as per the article published in July 2022 in PubMed, the researchers strongly emphasized the importance of cytogenetic study complemented with molecular cytogenetic study and karyotype-phenotype correlations in patients with Turner Syndrome to obtain information regarding the genotype-phenotype correlations related to the X chromosome. Thus, with the increase in the utilization of molecular cytogenetics in identifying the phenotypes in different genetic diseases, the demand for molecular cytogenetics is expected to register a significant rise in the forecast years.
Furthermore, technological advancements in the field of molecular cytogenetics are expected to drive market growth over the forecast period. For instance, in October 2022, Thermo Fisher Scientific upgraded its Applied Biosystems Chromosome Analysis Suite (ChAS) software through a collaboration with Genoox, a community-driven genomic data company. ChAS users will be able to access Genoox’s cloud-based AI platform, Franklin, with the launch of CytoScan Automated Interpretation and Reporting (AIR) solution, making cytogenetic research data analysis easier.
Hence, due to the rise in cancer and genetic disease, and the increase in studies associated with molecular cytogenetics, the studied market is anticipated to witness growth over the forecast period. However, the high cost of treatment and lack of awareness about the emerging diagnostic technologies in cytogenetics are likely to restrain the market growth over the study period.
Molecular Cytogenetics Market Trends
Cancer Segment is Expected to Show Better Growth Over the Forecast PeriodMolecular cytogenetics has played an important role in the rapid and precise characterization of cancer chromosome abnormalities. Oncology deals with the diagnosis and treatment of tumors and cancers. For instance, as per the Cancer Australia 2022 update, in 2022, it was estimated that 162,163 new cases of cancer were likely to be diagnosed in Australia (88,982 males and 73,181 females). Hence, a high prevalence of cancer is anticipated to utilize molecular cytogenetic tests to identify the severity, which thereby rises the segment growth over the forecast period.
Furthermore, as per the article published in March 2021 in PubMed, the Fluorescence in-situ hybridization (FISH) study has emerged as an indispensable tool for both basic and clinical research, as well as diagnostics, in leukemia and cancers. Chromosome abnormalities can be found via FISH by using fluorescently labeled DNA probes that target particular DNA sequences. Due to their ability to resolve complicated karyotypic abnormalities and perform a complete global scan for chromosomal imbalances, FISH-based procedures including multicolor karyotyping, comparative genomic hybridization (CGH), and array CGH have been used in growing clinical applications.
Moreover, workshops and seminars relating to cancer cytogenetics across the globe to advance cancer treatments are anticipated to boost market growth over the forecast period. For instance, European Cytogeneticists Association is planning to organize the '10th International Workshop on Cancer Genetic & Cytogenetic Diagnostics' in March 2023 focusing on all aspects concerning cancer cytogenetics in a diagnostic setting.
Hence, due to the surge in the different types of cancers, the increase in studies associated with molecular cytogenetics, and the rise in strategic alliances by the key players. the studied segment is anticipated to witness growth in the market over the forecast period.
North America is Expected to Hold a Significant Share in the Molecular Cytogenetics Market Over the Forecast PeriodThe molecular cytogenetics market is anticipated to witness significant growth in the North America region due to better healthcare infrastructure, effective government policies, a huge base of multinational companies, and a rise in genetic diseases. For instance, the Indiana Health Coverage Program module published in May 2022 covers chromosomal microarray analysis (CMA), also known as cytogenetic microarray analysis, when it is determined to be medically necessary for diagnosing a genetic abnormality in children with apparent nonsyndromic cognitive developmental delay/intellectual delay (DD/ID) or autism spectrum disorder (ASD), according to the latest accepted Diagnostic and Statistical Manual of Mental Disorders (DSM) guidelines.
Furthermore, as per the Canadian Cancer Society 2022 update, the estimated number of people diagnosed with cancer in 2022 was 233,900 in Canada. Breast, prostate, and colorectal cancers are the most prevalent cancers. Combined, they account for almost half of all prevalent cases. Thus, the high prevalence of cancer cases utilizes the applications offered by molecular cytogenetics in the North America region, which is therefore expected to drive the studied market over the forecast period.
Furthermore, in May 2022 Pfizer provided a medical grant which supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. The grant focused on the geographic scope of Canada and the grant was given for the study titled ‘Improving Cytogenetic Testing & Treatment Guidance in Adult AML’.
Hence, due to the better healthcare infrastructure and surge in research funding in molecular cytogenetics, and the rise in strategic alliances by the key players, North America is anticipated to hold a significant share of the market over the forecast period.
Molecular Cytogenetics Market Competitive AnalysisThe molecular cytogenetics market is moderately competitive in nature. The global players in the molecular cytogenetics market are Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F.Hoffmann-La Roche Ltd., Illumina, Inc., Oxford Gene Technology, PerkinElmer Inc, Quest Diagnostics and Thermo Fisher Scientific.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Growing Prevalence of Cancer and Genetic Disorders
4.2.2 Increasing Focus on Targeted Therapies for Cancer Treatment
4.2.3 Rise in Funding for Research and Clinical Diagnosis
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Lack of Awareness about the Emerging Diagnostic Technologies in Cytogenetics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.2 Kits & Reagents
5.1.3 Software & Services
5.2 By Technique
5.2.1 Fluorescence in Situ Hybridization
5.2.2 Comparative Genomic Hybridization
5.2.4 Other Techniques
5.3 By Application
5.3.2 Genetic Disorders
5.3.3 Other Applications
5.4.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6.1.1 Abbott Laboratories
6.1.2 Agilent Technologies, Inc.
6.1.3 Bio-Rad Laboratories, Inc.
6.1.4 F.Hoffmann-La Roche Ltd.
6.1.5 Illumina, Inc.
6.1.6 Oxford Gene Technology
6.1.7 PerkinElmer, Inc.
6.1.8 Quest Diagnostics
6.1.9 Thermo Fisher Scientific
6.1.10 Empire Genomics
6.1.11 Genial Genetic Solutions Ltd
6.1.12 CytoTest Inc.
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- F.Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Oxford Gene Technology
- PerkinElmer, Inc.
- Quest Diagnostics
- Thermo Fisher Scientific
- Empire Genomics
- Genial Genetic Solutions Ltd
- CytoTest Inc.